Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis

NCT01154049 | Completed Phase 1 DMC

• 1 other identifier: sm14-CT001P1
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase I, open-label, single arm trial, which aims to assess the safety of the vaccine prepared sm14 in healthy subjects. The product immunogenicity will be evaluated by conducting serology (anti-sm14 antibodies) and testing of cellular response to the antigen by the method ELI-SPOT. Each participant will remain in the study for approximately 4 months. The total study duration is 10 months, considering a period of 6 months for inclusion. Will be included in the study subjects male and female, between 18 and 49 years, that manifest their will to participate in the research by signing an Informed Consent Form. Eligible population for the study are subjects who do not present at screening significant changes in renal, cardiac and liver functions, complete blood count, clotting, present no acute or chronic illnesses, are not in the chronic use of any medication, do not have HIV infection or other immunodeficiency. Pregnant or breastfeeding women will not be included. Volunteers will receive three doses of vaccine prepared sm14, in doses containing 50 mcg of the antigen, associated with adjuvant GLA-SE at a dose of 10 mcg, with an interval of 30 days between each application. Twenty volunteers will be included in the study. This is a convenience sample, established for the first test of the product in humans, for the initial safety assessment.

Conditions

Schistosomiasis

Keywords

Schistosomiasis; Vaccine; sm14

Outcome Measures

Primary Outcomes (1)

• Safety of the vaccine

  Safety and tolerability of the vaccine (sm14 antigen plus GLA adjuvant) against schistosomiasis in health adults

  4 months after the first dose

Secondary Outcomes (2)

• Proportion of seroconversion

  30 days after the third vaccine dose

• Cellular immune response to sm-14 vaccination in health adults

  30 days after the third vaccine dose

Study Arms (1)

single arm

EXPERIMENTAL

3 doses of the vaccine, on days 0, 30 and 60.

Biological: sm14 antigen plus adjuvant GLA

Interventions

sm14 antigen plus adjuvant GLA BIOLOGICAL

Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.

single arm

Eligibility Criteria

• Age: 18 Years - 49 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Aged between 18 and 49 years.
• Available for follow-up throughout the study period (approximately 120 days).
• Ability to understand and sign the informed consent form (IC).
• HIV serology negative
• Patients who has not chronic use or have not used in the past 45 days any medication, except trifling as nasal saline and vitamins.
• Be in good health without significant medical history.
• Screening physical examination without clinical significant abnormalities.
• Screening laboratory tests without significant abnormalities according to normal standards and the evaluation of investigators.
• Additional criteria for females of childbearing potential: Negative pregnancy test at screening; consistent use of contraceptive methods (male or female condom, diaphragm, IUD and oral contraceptives or "patches").

You may not qualify if:

• Women who are pregnant or breastfeeding.
• Use of cytotoxic or immunosuppressive drugs in the last six months, except for spray nasal corticosteroids for allergic rhinitis or topical corticosteroids for uncomplicated dermatitis.
• Immunoglobulin use 60 days prior to vaccination.
• Use of any type of vaccine 30 days prior to vaccination.
• Plan to receive any other vaccine during the period of participation in the study (four months)
• Use any type of investigational medication in a period of 30 days prior to vaccination
• Use of allergy shots with antigens within 14 days prior to vaccination.
• Presence of neurological disease, liver disease or kidney disease (diseases which have led to hospitalization or prolonged treatment).
• History of sickle cell anemia.
• Asplenia (no spleen or its removal).
• History of alcohol use/abuse (CAGE criterion) or illicit drugs.
• Blood pressure above 140/90 mmHg at screening or hypertension requiring drug treatment.
• Coagulopathy diagnosed by a doctor or report of capillary fragility (eg, bruising, bleeding, etc.) after injections or blood sampling.
• Active malignancy (eg, any type of cancer) or treated so it may relapse during the study.
• History of allergy to vaccines containing adjuvants composed of lipids (GLA or MPL)

Sponsors & Collaborators

• Oswaldo Cruz Foundation: lead
• Financiadora de Estudos e Projetos: collaborator

Study Sites (1)

Instituto de Pesquisa Clínica Evandro Chagas (IPEC) - Fiocruz

Rio de Janeiro, Rio de Janeiro, 21040900, Brazil

Location

Related Publications (1)

• Santini-Oliveira M, Coler RN, Parra J, Veloso V, Jayashankar L, Pinto PM, Ciol MA, Bergquist R, Reed SG, Tendler M. Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults. Vaccine. 2016 Jan 20;34(4):586-594. doi: 10.1016/j.vaccine.2015.10.027. Epub 2015 Nov 10.

  PMID: 26571311 DERIVED

MeSH Terms

Conditions

Schistosomiasis

Condition Hierarchy (Ancestors)

Trematode Infections; Helminthiasis; Parasitic Diseases; Infections; Vector Borne Diseases

Study Officials

• Marilia S Oliveira, MD, MsC

  Instituto de Pesquisa Clínica Evandro Chagas (IPEC)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 29, 2010
• First Posted: June 30, 2010
• Study Start: March 1, 2011
• Primary Completion: April 1, 2014
• Study Completion: April 1, 2014
• Last Updated: August 10, 2016

Record last verified: 2016-08

Locations

BR (1)